Financial Results - The unaudited consolidated financial results for the six months ending June 30, 2024, have been announced, comparing with the same period in 2023[1]. - Revenue for the six months ended June 30, 2024, was RMB 11,918,000, an increase of 3.95% compared to RMB 11,465,000 for the same period in 2023[84]. - The Group recorded a gross profit of approximately RMB 8.0 million during the Reporting Period, representing an increase of approximately RMB 445,000, or 5.9% from approximately RMB 7.5 million during the Corresponding Period[21]. - The loss attributable to owners of the Company was approximately RMB 1.8 million, compared to approximately RMB 1.5 million during the Corresponding Period, primarily due to increased research and development expenses[24]. - Basic loss per share during the Reporting Period was RMB 0.38 cents, compared to RMB 0.35 cents during the Corresponding Period[25]. Compliance and Governance - The company confirms that the information provided in the report is accurate and complete in all material respects, with no misleading or deceptive elements[5]. - The report adheres to the GEM Listing Rules, ensuring compliance with the regulations set by the Stock Exchange of Hong Kong[6]. - The board of directors collectively accepts full responsibility for the report's contents, ensuring accountability for the information presented[5]. - The company has adopted and complied with the Corporate Governance Code during the reporting period[66]. - The Audit Committee consists of three independent non-executive Directors, ensuring compliance with GEM Listing Rules[77]. Revenue and Profitability - The Group's revenue increased by approximately RMB 453,000, or 4.0%, from approximately RMB 11.5 million for the six months ended June 30, 2023, to approximately RMB 11.9 million for the Reporting Period[17]. - Revenue from the sales of biological reagents and auxiliary reproductive supplies and equipment increased by approximately RMB 516,000, or 4.5% during the Reporting Period[11]. - Other income decreased by approximately RMB 56,000 or approximately 15.0%, from approximately RMB 374,000 during the Corresponding Period to approximately RMB 318,000 during the Reporting Period[23]. - The gross profit margin slightly increased from approximately 65.8% during the Corresponding Period to approximately 67.0% during the Reporting Period[21]. Expenses and Losses - Selling and distribution expenses increased by approximately RMB138,000 or approximately 3.7%, from approximately RMB3.8 million to approximately RMB3.9 million during the Reporting Period[24]. - Administrative expenses rose from approximately RMB4.2 million to approximately RMB4.3 million, representing an increase of approximately RMB52,000 or approximately 1.2%[24]. - Research and development expenses significantly increased by approximately RMB399,000 or approximately 25.0%, from approximately RMB1.6 million to approximately RMB2.0 million during the Reporting Period[24]. - The loss for the period attributable to the owners of the Company was RMB 1,779,000, compared to a loss of RMB 1,455,000 in the prior year, indicating a 22.3% increase in loss[84]. Cash Flow and Financial Position - As of June 30, 2024, the total cash and bank balances of the Group were approximately RMB36.7 million, an increase from RMB32.9 million as of December 31, 2023, primarily due to proceeds from the placing of new shares[39]. - Net cash used in operating activities was RMB (2,819,000), compared to RMB 39,000 in the same period of 2023[94]. - Total current assets increased to RMB 46,664,000 as of June 30, 2024, compared to RMB 40,340,000 at the end of 2023, reflecting a growth of 15.8%[86]. - The Group's total liabilities and financial obligations are being managed effectively, with a focus on maintaining liquidity and operational efficiency[129]. Share Capital and Equity - The issued and fully paid ordinary shares increased to 500,472,000 shares as of June 30, 2024, from 418,472,000 shares as of December 31, 2023, reflecting an increase of about 19.6%[134]. - The total equity attributable to owners of the Company amounted to approximately RMB56.5 million as of June 30, 2024, compared to approximately RMB51.0 million as of December 31, 2023[39]. - The total share capital as of June 30, 2024, was RMB 4,432,000, compared to RMB 3,674,000 as of December 31, 2023, marking an increase of approximately 20.6%[134]. Strategic Initiatives - Future strategic priorities include continuing research and development on diagnostic testing and seeking partnerships to strengthen the supplements business[16]. - The Group intends to commence trading of enzyme-based products through an online sales platform and business-to-business product trading[12]. - The Group aims to apply for medical device registration for rapid point-of-care diagnostic testing using immunoassay techniques once satisfactory results are achieved[16]. Employee and Management Information - The Group had 90 full-time employees as of June 30, 2024, a decrease from 96 employees as of December 31, 2023[41]. - Compensation for key management personnel increased to RMB 1,025,000 for the six months ended June 30, 2024, compared to RMB 962,000 for the same period in 2023, representing a rise of about 6.6%[139]. Risks and Market Position - The company emphasizes the potential risks associated with investing in GEM-listed companies, advising investors to consider these risks carefully[3]. - The company is positioned in the GEM market, which is designed for small and mid-sized companies, indicating a higher investment risk compared to other companies listed on the Stock Exchange[3].
华康生物医学(08622) - 2024 - 中期业绩